2025 – 2026 In-Cycle Grants Award Program (Research Grant)

2025 – 2026 In-Cycle Grants Award Program (Research Grant) is sponsored by Alpha-1 Foundation. Supports research efforts aimed at improving the health of individuals with Alpha-1 Antitrypsin Deficiency, focusing on understanding the basic biology and pathogenesis of the condition.

Alpha-1 Foundation Grantees & Research Research funded by the Alpha-1 Foundation (A1F) has greatly improved our understanding of the biological underpinnings and clinical manifestations of Alpha-1 and has identified novel drug targets likely to lead to new therapeutic solutions.

The Alpha-1 Foundation offers opportunities for data sharing among researchers supported by A1F grants and contracts through our DNA and Tissue Bank and Research Registry 2025-2026 In-Cycle Grant Recipients Brigham and Women’s Hospital “Exposomic and Multiomic Predictors of Progression in Alpha-1 Antitrypsin Deficiency” JWW Career Development Grant University of Alabama at Birmingham “ Longitudinal Transcriptomics in Respiratory Exacerbations in Alpha and Non-Alpha COPD “ Pilot and Feasibility Grant Brigham and Women’s Hospital, Inc. “ Using Dynamic Networks to Identify AATD Mechanisms Impacting Therapeutic Efficiency “ Medical University of Graz “ Rubicon Inhibition as a Novel Therapy for A1AT Liver Disease “ University of Nebraska-Lincoln “Designer Milk Exosomes for Delivering Gene Therapy in Alpha-1 Antitrypsin Deficiency” Francesco Annunziata, PhD “ A Dual Therapy for AATD: Combining N-degron mediated ER-phagy and Gene Correction” “Alpha-1 Antitrypsin Polymers and Autophagy Impairments in Human Lung Macrophages” Postdoctoral Research Fellowship Grant Brigham and Women’s Hospital, Inc. “ Somatic Disease Modifiers in Alpha-1 Antitrypsin Deficiency Lung Cells “ Brigham and Women’s Hospital, Inc. “Multi-omics of Mosaic Loss of Y chromosome and Alpha-1 Antitrypsin Deficiency” “Patient and Physician Understanding and Attitudes Towards Genetic Therapies in Severe AATD” Brigham and Women’s Hospital, Inc. “Programmable Gene Integration for Mutation-Agnostic Therapy of AATD” Cambridge Institute for Medical Research – University of Cambridge “Identifying the Molecular Mechanism of ER Dysfunction in Alpha-1 Antitrypsin Deficiency” Medical University of Graz “Activation of the PXR-TFEB-Autophagy Network to Treat Alpha-1-Antitrypsin Deficiency” “Spatial Quantification of Radiographic Emphysema in the A1BC Cohort” Cleveland Clinic Foundation “Levels of Intracellular Accumulation of PiZ Mutant and Liver Disease Severity” University College London “Beyond the Z Variant: Alternative Polymers in Alpha-1 Antitrypsin Deficiency” Cleveland Clinic Foundation “Sarcopenia Risk and Mechanisms in Alpha-1 Antitrypsin Deficiency “ University of Alabama at Birmingham “Modeling Early Airway Pathogenesis: Aging-Associated RASC Dysfunction in AAT Deficiency” “Role of Macrophages in Clearance and Inflammatory Response to Extracellular AAT Polymers” University of Naples Federico II, Naples “Translocation Inhibitors to Counteract ATZ Toxic Accumulation” University of Kansas Medical Center Research Institute, Inc. “AI-Enhanced Quantitative CT Lung-Structure Function Analysis to Improve Detection of AATD” University of Texas at Austin “Inhalable and Non-Viral DNA Nanocomplex for Alpha-1 Antitrypsin Deficiency” Alpha-1 Research Registry Find an Alpha-1 Specialist Find a Local A1F Support Group Clinical Resource Centers (CRCs) Clinical Practice Guidelines Healthcare Provider’s Guide Continuing Medical Education (CME) Credits A1F Patient Information Line A1F Fred C.

Walsh Speaker Bureau Coral Gables, Florida 33134 Toll Free: (877) 2-CURE-A1